GoingToMeet

Background Info

Key Speakers

 • Dr. Maria Flocco, Senior Director, Lead Discovery and Structural Biology & Biophysics, Pfizer

• Dr. Magalie Rocheville, Investigator, Molecular Discovery Research, GlaxoSmithKline

• Dr. Priya Kunapuli, Director, In Vitro Sciences, External Discovery and Pre-Clinical Sciences, Merck Research Laboratories

• Dr. Stefan O. Mueller, Global Head, Early, Genetic and Molecular Toxicology, Merck Serono • Professor Sir Ian Wilmut, Director, MRC Centre for Regenerative Medicine, University of Edinburgh

• Dr. Matthew Peters, Principal Scientist, Lead Generation, AstraZeneca • Dr. Alastair Brown, Associate Principal Scientist, AstraZeneca

• Dr. Nick Thomas, Principal Scientist, GE Healthcare

• Dr. Rochdi Bouhelal, Senior Investigator, Novartis

• Dr. Daniella Steel, Senior Principal Scientist, Cellartis

• Dr. Julian Burke, Chief Scientific Officer, Genetix

• Dr. Dusko Ilic, Senior Lecturer in Stem Cell Science, King’s College London

• Dr. Jurgen Moll, Director, Department of Cell Biology & Oncology, Nerviano Medical Sciences

• Dr. Stephan Heyse, Head of Lead Discovery Informatics, Genedata

Despite spiralling R&D costs, 90% of lead candidates identified by current in vitro systems fail to become drugs. Setbacks including poor efficacy and unanticipated side effects remain significant challenges, frequently undetected in animal and pre-clinical testing. New advances in microarray, label-free and stem cell platforms are facilitating faster screening using human cells and dramatically improving next generation models. This 3-day event, comprising pre-conference workshop and two-day meeting, provides practical insights into the latest developments in this exciting field. With an international faculty of leading experts, accelerate your product launches with insights from key decision makers. By attending Visiongain's Cell-Based assays conference, you will obtain distilled insights from outstanding speakers, in key areas including:

• • Whole-cell screening for GPCR ligands
• • Direct small-molecule kinase activation
• • Advances and challenges in label-free technologies
• • Induced pluripotent and hESCs for drug discovery
• • Embryonic stem cell-derived hepatocytes and adult liver cells for CYP450 toxicity evaluation
• • Accelerated high-content screening with human cardiac cells
• • Neural progenitor cells for HT/uHT testing
• • Three-dimensional primary cell cultures for drug development
• • Cell migration and uptake assays
• • Primary and three-dimensional culture methods for pharmacological profiling